Researchers analysed thousands of laboratory-made plasmids and discovered that nearly half of them had defects, raising questions of experimental reproducibility.
Aggregated News
Ostensibly, pharmacogenomics is all about the individual, not about race. Indeed, part of its promise is its purported ability to move beyond race, to render it irrelevant as a biological category in assessing drugs response. Yet pharmacogenomics remains in its infancy. Some progress has been made, but a recent report from the Royal Society in the United Kingdom asserts that realizing the promise of truly individualized pharmacogenomic therapies remains decades away. Nonetheless, major government, academia, and industry initiatives are drawing huge amounts of material and intellectual capital into the pursuit of this distant promise.
I am...